Imaging evaluation of lung cancer treated with PD-1/PD-L1 inhibitors

被引：4
|
作者：
Mohammed, Nader [1 ]
Zhou, Rong Rong [2 ]
Xiong, Zeng [1 ]
机构：
[1] Cent South Univ, Xiangya Hosp, Dept Radiol, Changsha, Peoples R China
[2] Cent South Univ, Xiangya Hosp, Dept Oncol, Changsha, Peoples R China
来源：
BRITISH JOURNAL OF RADIOLOGY | 2021年 / 94卷 / 1127期
关键词：
IMMUNE-RELATED RESPONSE; ADVERSE EVENTS; CHECKPOINT INHIBITORS; TUMOR RESPONSE; HYPERPROGRESSIVE DISEASE; EVALUATION CRITERIA; ADVANCED MELANOMA; IMMUNOTHERAPY; PNEUMONITIS; NIVOLUMAB;
D O I：
10.1259/bjr.20210228
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
Immunotherapy (PD-1/PD- L1 inhibitors) has attracted attention for lung cancer treatment and recasted the administration of immunotherapeutics to patients who have advanced/metastatic diseases. Whether in combination or as monotherapy, these medications have become common therapies for certain patients with lung cancer. Moreover, their usage is expected to expand widely in the future. This review aims to discuss the imaging evaluation of lung cancer response to PD-1/PD- L1 therapy with focus on new radiological criteria for immunotherapy response. Abnormal radiological responses (pseudoprogression, dissociative responses, and hyperprogression) and immune-related adverse events are also described.
引用
收藏
页数：9
相关论文
共 50 条
  • [1] Herpes zoster in lung cancer patients treated with PD-1/PD-L1 inhibitors
    Taoka, Masataka
    Ochi, Nobuaki
    Yamane, Hiromichi
    Yamamoto, Takenobu
    Kawahara, Tatsuyuki
    Uji, Emiko
    Kosaka, Youko
    Takeda, Kouhei
    Nagasaki, Yasunari
    Nakanishi, Hidekazu
    Aoyama, Yumi
    Takigawa, Nagio
    TRANSLATIONAL CANCER RESEARCH, 2022, 11 (03) : 456 - 462
  • [2] Soluble PD-L1 levels correlate with efficacy of PD-1/PD-L1 inhibitors in lung cancer
    Kang, Da Hyun
    Koh, Jeong Suk
    Chung, Chaeuk
    Park, Dongil
    Lee, Song-I
    Lee, Jeong Eun
    RESPIROLOGY, 2023, 28 : 99 - 99
  • [3] PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer
    Monneur, Audrey
    Goncalves, Anthony
    Bertucci, Francois
    BULLETIN DU CANCER, 2018, 105 (03) : 261 - 272
  • [4] PD-1/PD-L1 Inhibitors in Cervical Cancer
    Liu, Yuncong
    Wu, Li
    Tong, Ruizhan
    Yang, Feiyue
    Yin, Limei
    Li, Mengqian
    You, Liting
    Xue, Jianxin
    Lu, You
    FRONTIERS IN PHARMACOLOGY, 2019, 10
  • [5] PD-1/PD-L1 inhibitors
    Sunshine, Joel
    Taube, Janis M.
    CURRENT OPINION IN PHARMACOLOGY, 2015, 23 : 32 - 38
  • [6] PD-1/PD-L1 Axis in Lung Cancer
    Santini, Fernando C.
    Hellmann, Matthew D.
    CANCER JOURNAL, 2018, 24 (01): : 15 - 19
  • [7] Combination therapy with PD-1 or PD-L1 inhibitors for cancer
    Hayashi, Hidetoshi
    Nakagawa, Kazuhiko
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (05) : 818 - 830
  • [8] Combination therapy with PD-1 or PD-L1 inhibitors for cancer
    Hidetoshi Hayashi
    Kazuhiko Nakagawa
    International Journal of Clinical Oncology, 2020, 25 : 818 - 830
  • [9] Effectiveness of PD-1/PD-L1 inhibitors in the treatment of lung cancer: Brightness and challenge
    Ying Yang
    Yongfeng Yu
    Shun Lu
    Science China Life Sciences, 2020, 63 : 1499 - 1514
  • [10] Effectiveness of PD-1/PD-L1 inhibitors in the treatment of lung cancer: Brightness and challenge
    Ying Yang
    Yongfeng Yu
    Shun Lu
    Science China(Life Sciences), 2020, 63 (10) : 1499 - 1514
12345